# Dilated Cardiomyopathy

## Guidelines

### Key Sources

The following summarized guidelines for the evaluation and management of dilated cardiomyopathy are prepared by our editorial team based on guidelines from the European Society of Cardiology (ESC 2023,2022,2021), the Heart Failure Society of America (HFSA/AHA/ACC 2022), the American Heart Association (AHA/ASA 2021), the American Heart Association (AHA/HRS/ACC 2018), the American Heart Association (AHA 2016), the American Heart Association (AHA/ACC 2015), and the European Heart Rhythm Association (EHRA/HRS 2011).

## Clinical Findings

### Symptoms
- Abdominal discomfort
- Dyspnea
- Exercise intolerance
- Fatigue
- Loss of appetite
- Nausea
- Orthopnea
- Palpitations
- Syncope
- Weight loss

### Vital Signs
- Tachycardia
- ↓ SBP (decreased systolic blood pressure)

### Past Medical History
- Acromegaly
- Alcohol use disorder
- Amyloidosis
- Becker muscular dystrophy
- Chagas disease
- Congenital heart disease
- Cushing's syndrome
- Dermatomyositis
- Diabetes mellitus
- Duchenne muscular dystrophy
- Eosinophilic granulomatosis with polyangiitis
- Exposure to chemotherapy
- Granulomatosis with polyangiitis
- HF (Heart Failure)
- Hyperthyroidism
- Hypothyroidism
- Kawasaki disease
- Myocarditis
- Myotonic dystrophy
- Obesity
- Polyarteritis nodosa
- SLE (Systemic Lupus Erythematosus)
- Sarcoidosis
- Scleroderma
- Substance use disorder
- Valvular heart disease

## Studies

### 2025 • TRAVERSE
In adult patients with LV arrhythmias undergoing catheter ablation procedures, transseptal puncture approach was superior to retrograde aortic approach with respect to acute brain lesion on postprocedural MRI.
**Reference:** Gregory M Marcus et al. Circulation. 2025 Apr 15. [PubMed](https://pubmed.ncbi.nlm.nih.gov/search/?term=Gregory+M+Marcus+TRAVERSE+2025)

### 2024 • SPEC-AI Nigeria
In pregnant or postpartum (up to 12 months) women aged 18-49 years, AI-guided screening was superior to usual care with respect to detection of LV systolic dysfunction, using an AI-enabled digital stethoscope in AI group.
**Reference:** Demilade A Adedinsewo et al. Nat Med. 2024 Oct. [PubMed](https://pubmed.ncbi.nlm.nih.gov/search/?term=Demilade+A+Adedinsewo+SPEC-AI+2024)

### 2024 • ATTRibute-CM
In patients with transthyretin amyloid cardiomyopathy, acoramidis was superior to placebo with respect to favorable pairwise comparisons in a hierarchical outcome of death from any cause, cardiovascular-related hospitalization, change from baseline in the NT-proBNP level, and change from baseline in the 6-minute walk distance at month 30.
**Reference:** Julian D Gillmore et al. N Engl J Med. 2024 Jan 11. [PubMed](https://pubmed.ncbi.nlm.nih.gov/search/?term=Julian+D+Gillmore+ATTRibute-CM+2024)

### 2022 • PARTITA
In patients with dilated cardiomyopathy who received implantable cardioverter defibrillator shock for VT, ablation was superior to standard therapy with respect to the composite outcome of death from any cause or hospitalization for worsening HF.
**Reference:** Paolo Della Bella et al. Circulation. 2022 Jun 21. [PubMed](https://pubmed.ncbi.nlm.nih.gov/search/?term=Paolo+Della+Bella+PARTITA+2022)

### 2022 • PAUSE-SCD
In patients with cardiomyopathy and monomorphic VT with an indication for ICD implantation, ablation therapy was superior to conventional therapy with respect to the composite outcome of VT recurrence, cardiovascular hospitalization or death.
**Reference:** Roderick Tung et al. Circulation. 2022 Jun 21. [PubMed](https://pubmed.ncbi.nlm.nih.gov/search/?term=Roderick+Tung+PAUSE-SCD+2022)

### 2020 • BERLIN-VT
In patients with stable ischemic cardiomyopathy, a LVEF between 30-50%, and VT, preventive ablation was not superior to deferred ablation with respect to the composite of death and unplanned hospitalization for symptomatic ventricular arrhythmia or worsening HF.
**Reference:** Stephan Willems et al. Circulation. 2020 Mar 31. [PubMed](https://pubmed.ncbi.nlm.nih.gov/search/?term=Stephan+Willems+BERLIN-VT+2020)

### 2018 • ATTR-ACT
In patients with transthyretin amyloid cardiomyopathy, tafamidis was superior to placebo with respect to a all-cause death.
**Reference:** Maurer MS et al. N Engl J Med. 2018 Sep 13. [PubMed](https://pubmed.ncbi.nlm.nih.gov/search/?term=Maurer+MS+ATTR-ACT+2018)

### 2016 • VANISH (ventricular tachycardia)
In patients with ischemic cardiomyopathy and an ICD who had VT despite the use of antiarrhythmic drugs, catheter ablation was superior to escalated antiarrhythmic therapy with respect to death, VT storm, or appropriate ICD shock.
**Reference:** Sapp JL et al. N Engl J Med. 2016 Jul 14. [PubMed](https://pubmed.ncbi.nlm.nih.gov/search/?term=Sapp+JL+VANISH+2016)

### 2009 • MADIT-CRT
In patients with ischemic or nonischemic cardiomyopathy, an ejection fraction ≤ 30%, a QRS duration ≥ 130 ms, and NYHA class I or II symptoms, CRT plus ICD implantation was superior to ICD implantation only with respect to death from any cause or a nonfatal heart-failure event.
**Reference:** Moss AJ et al. N Engl J Med. 2009 Oct 1. [PubMed](https://pubmed.ncbi.nlm.nih.gov/search/?term=Moss+AJ+MADIT-CRT+2009)

### 2007 • CORONA
In patients with systolic HF (NYHA class II, III or IV) secondary to ischemic cardiomyopathy, rosuvastatin was not superior to placebo with respect to death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke.
**Reference:** Kjekshus J et al. N Engl J Med. 2007 Nov 29. [PubMed](https://pubmed.ncbi.nlm.nih.gov/search/?term=Kjekshus+J+CORONA+2007)

### 2004 • DEFINITE
In patients with nonischemic dilated cardiomyopathy, an LVEF < 36%, and premature ventricular complexes or nonsustained VT, implantation of a cardioverter-defibrillator was superior to standard medical therapy alone with respect to sudden death from arrhythmia.
**Reference:** Kadish A et al. N Engl J Med. 2004 May 20. [PubMed](https://pubmed.ncbi.nlm.nih.gov/search/?term=Kadish+A+DEFINITE+2004)

### 1996 • DiDi
In patients with idiopathic dilated cardiomyopathy diagnosed by coronary angiography, catheterization of left side of heart, and LVEF < 0.50, diltiazem was not superior to placebo with respect to transplant listing-free survival.
**Reference:** H R Figulla et al. Circulation. 1996 Aug 1. [PubMed](https://pubmed.ncbi.nlm.nih.gov/search/?term=H+R+Figulla+DiDi+1996)

## Screening and Diagnosis

### Screening of Family Relatives

**As per ESC 2023 guidelines:**

(B)
- Obtain cascade genetic testing, with pre- and post-test counseling, in adult at-risk relatives of a patient with cardiomyopathy with a confident genetic diagnosis (a pathogenic/likely pathogenic variant) in the family (starting with first-degree relatives, if available, and cascading out sequentially).

(C)
- Consider obtaining cascade genetic testing with pre- and post-test counseling in pediatric at-risk relatives of a patient with cardiomyopathy with a confident genetic diagnosis (a pathogenic/likely pathogenic variant) in the family (starting with first-degree relatives, if available, and cascading out sequentially), considering the underlying cardiomyopathy, expected age of onset, presentation in the family, and clinical/legal consequences.
- Consider obtaining testing for the presence of a familial variant of unknown significance, typically in parents and/or affected relatives, to determine if the variant segregates with the cardiomyopathy phenotype and if this might allow the variant to be interpreted with confidence.
- Consider obtaining a clinical evaluation of close relatives (second-degree relatives of the index patient) during cascade screening where a first-degree relative has died.
- Consider obtaining contrast-enhanced cardiac MRI in genotype-positive/phenotype-negative family members to aid diagnosis and detection of early disease in families with cardiomyopathy with an identified disease-causing variant.
- Consider obtaining contrast-enhanced cardiac MRI in phenotype-negative family members to aid diagnosis and detect early disease in cases of familial cardiomyopathy without a genetic diagnosis.

(D)
- Do not obtain diagnostic genetic testing in phenotype-negative relatives of a patient with cardiomyopathy in the absence of a confident genetic diagnosis (a pathogenic/likely pathogenic variant) in the family.

(B)
- Obtain clinical evaluation using a multiparametric approach, including ECG, cardiac imaging, and long-term follow-up, in first-degree relatives with the same disease-causing variant as the proband after cascade genetic testing.
- Discharge first-degree relatives without a phenotype and not having the same disease-causing variant as the proband after cascade genetic testing from further follow-up, but advise seeking re-assessment in case symptoms develop or when new clinically relevant data emerge in the family.
- Obtain initial clinical evaluation using a multiparametric approach, including ECG and cardiac imaging, in first-degree relatives when no pathogenic/likely pathogenic variant is identified in the proband or genetic testing is not obtained.

(C)
- Consider obtaining regular, long-term clinical evaluation using a multiparametric approach, including ECG and cardiac imaging, in first-degree relatives when no pathogenic/likely pathogenic variant is identified in the proband or genetic testing is not obtained.

**As per ESC 2022 guidelines:**

(B)
- Obtain an ECG and echocardiography in a first-degree relative of patients with dilated cardiomyopathy if:
  - the index patient was diagnosed at < 50 years of age or has clinical features suggestive of an inherited cause
  - there is a family history of dilated cardiomyopathy or premature unexpected sudden death

(C)
- Consider obtaining an ECG and echocardiography in a first-degree relative of patients with apparently sporadic dilated cardiomyopathy.

**As per ACC/AHA/HFSA 2022 guidelines:**

(B)
- Offer genetic screening and counseling in first-degree relatives of selected patients with genetic or inherited cardiomyopathies to detect cardiac disease and prompt consideration of treatments to decrease HF progression and sudden death.

**As per AHA 2016 guidelines:**

(B)
- Elicit a 3-generational family history to aid in establishing the diagnosis of familial dilated cardiomyopathy in patients with idiopathic dilated cardiomyopathy.
- Obtain periodic serial echocardiographic screening with an assessment of LV function and size in first-degree relatives of patients with familial cardiomyopathy. Consider obtaining periodic serial echocardiographic screening with an assessment of LV function and size in first-degree relatives of patients with idiopathic cardiomyopathy.
- Obtain mutation-specific genetic testing in family members and appropriate relatives after the identification of a dilated cardiomyopathy-causative mutation in the index case.

**As per EHRA/HRS 2011 guidelines:**

(A)
- Obtain mutation-specific genetic testing in family members and appropriate relatives following the identification of a dilated cardiomyopathy-causative mutation in the index case.

## Diagnostic Investigations

### General Principles

**As per ESC 2023 guidelines:**

(B)
- Obtain systematic evaluation in all patients with suspected or established cardiomyopathy using a multiparametric approach, including clinical evaluation, pedigree analysis, ECG, Holter monitoring, laboratory tests, and multimodality imaging.

### History and Physical Examination

**As per ESC 2023 guidelines:**

(B)
- Elicit family history and create a three- to four-generation family tree in all patients with suspected cardiomyopathy to aid in diagnosis, provide clues to underlying etiology, determine inheritance patterns, and identify at-risk relatives.

### TTE (Transthoracic Echocardiography)

**As per ESC 2023 guidelines:**

(B)
- Obtain a comprehensive evaluation of cardiac dimensions and LV and RV systolic (global and regional) and LV diastolic function in all patients with cardiomyopathy at initial evaluation and during follow-up to monitor disease progression and aid risk stratification and management.

### Cardiac MRI

**As per ESC 2023 guidelines:**

(B)
- Obtain contrast-enhanced cardiac MRI in the initial evaluation of patients with cardiomyopathy.

**As per ESC 2022 guidelines:**

(C)
- Consider obtaining cardiac MRI with late gadolinium enhancement to assess the etiology and the risk of ventricular arrhythmia/SCD in patients with dilated cardiomyopathy.

**As per ESC 2021 guidelines:**

(C)
- Consider obtaining cardiac MRI with late gadolinium enhancement in patients with dilated cardiomyopathy to distinguish between ischemic and non-ischemic myocardial damage.

**As per ACC/AHA/HRS 2018 guidelines:**

(B)
- Consider obtaining cardiac MRI with late gadolinium enhancement for diagnosis in patients with suspected non-ischemic cardiomyopathy from myocardial infiltrative processes.

(C)
- Consider obtaining cardiac MRI with late gadolinium enhancement for assessing the risk of sudden cardiac arrest/SCD in patients with suspected non-ischemic cardiomyopathy.

### Cardiac CT

**As per ESC 2023 guidelines:**

(C)
- Consider obtaining contrast-enhanced cardiac CT in patients with suspected cardiomyopathy having inadequate echocardiographic imaging and contraindications to cardiac MRI.
- Consider obtaining CT-based imaging to exclude congenital or acquired coronary artery disease as a cause of the observed myocardial abnormality in patients with suspected cardiomyopathy.
- Consider obtaining 18F-FDG-PET in the evaluation of patients with cardiomyopathy if cardiac sarcoidosis is suspected.

### Nuclear Imaging

**As per ESC 2023 guidelines:**

(B)
- Obtain 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid, -PYP, -HMDP bone-tracer scintigraphy in patients with suspected transthyretin amyloidosis-related cardiac amyloidosis.

### Laboratory Tests

**As per ESC 2023 guidelines:**

(B)
- Obtain routine first-line laboratory tests in all patients with suspected or confirmed cardiomyopathy to evaluate etiology, assess disease severity, and aid in detecting extracardiac manifestations and assessing secondary organ dysfunction.

(C)
- Consider obtaining additional tests in patients with cardiomyopathy and extracardiac features to aid in detecting metabolic and syndromic causes following specialist evaluation.

### Genetic Testing

**As per ESC 2023 guidelines:**

(B)
- Obtain genetic testing in patients fulfilling diagnostic criteria for cardiomyopathy in cases where it enables diagnosis, prognostication, therapeutic stratification, or reproductive management of the patient or where it enables cascade genetic evaluation of their relatives otherwise eligible for enrollment into long-term surveillance.
- Obtain genetic testing for a deceased individual identified to have cardiomyopathy at post-mortem if a genetic diagnosis would facilitate the management of surviving relatives.
- Obtain genetic testing for cardiomyopathy with access to a multidisciplinary team with expertise in genetic testing methodology, sequence variant interpretation, and clinical application of genetic testing, typically in a specialized cardiomyopathy service or in a network model with access to equivalent expertise.

(C)
- Consider obtaining genetic testing in patients fulfilling diagnostic criteria for cardiomyopathy when it will have a net benefit to the patient, considering the psychological impact and preference, even if it does not enable diagnosis, prognostication, therapeutic stratification, or cascade genetic screening of their relatives.
- Consider obtaining genetic testing in patients with a borderline phenotype not fulfilling diagnostic criteria for cardiomyopathy only after detailed assessment by specialist teams.

**As per ESC 2022 guidelines:**

(B)
- Obtain genetic testing (including at least lamin A/C, PLN, RBM20, and FLNC genes) in patients with dilated cardiomyopathy and atrioventricular conduction delay at < 50 years, or having a family history of dilated cardiomyopathy or SCD in a first-degree relative (at age < 50 years).

(C)
- Consider obtaining genetic testing (including at least lamin A/C, PLN, RBM20, and FLNC genes) for risk stratification in patients with apparently sporadic dilated cardiomyopathy presenting at a young age or with signs of suspicion for an inherited etiology.

**As per ACC/AHA/HFSA 2022 guidelines:**

(C)
- Consider referring selected patients with non-ischemic cardiomyopathy for genetic counseling and testing to identify conditions likely to guide treatment in patients and family members.

**As per ACC/AHA/HRS 2018 guidelines:**

(C)
- Consider providing genetic counseling and obtaining genetic testing in patients with non-ischemic cardiomyopathy developing conduction disease or LV dysfunction at < 40 years of age or having a family history of non-ischemic cardiomyopathy or SCD in a first-degree relative (< 50 years of age) to detect a heritable disease to clarify prognosis and facilitate cascade screening of relatives.

**As per AHA 2016 guidelines:**

(C)
- Consider obtaining genetic testing in conjunction with genetic counseling in patients with familial or idiopathic cardiomyopathy.

(B)
- Consider obtaining genetic testing in patients with familial dilated cardiomyopathy to confirm the diagnosis, to facilitate cascade screening within the family, and to help with family planning.

**As per EHRA/HRS 2011 guidelines:**

(A)
- Obtain comprehensive or targeted (LMNA and SCN5A) genetic testing in patients with dilated cardiomyopathy and significant cardiac conduction disease (first-, second-, or third-degree heart block) and/or a family history of premature unexpected sudden death.

(C)
- Consider obtaining genetic testing in patients with familial dilated cardiomyopathy to confirm the diagnosis, identify patients at the highest risk of arrhythmia and syndromic features, facilitate cascade screening within the family, and help with family planning.

## Diagnostic Procedures

### Electrophysiology Study

**As per ESC 2022 guidelines:**

(C)
- Consider obtaining electrophysiological evaluation in patients with dilated cardiomyopathy when syncope remains unexplained after noninvasive evaluation.

**As per ACC/AHA/HRS 2018 guidelines:**

(C)
- Consider obtaining electrophysiologic testing to evaluate the risk of sustained VT in patients with non-ischemic cardiomyopathy presenting with syncope or other ventricular arrhythmia symptoms and not meeting indications for a primary prevention ICD.
- Consider performing ICD placement or obtaining electrophysiologic testing for risk stratification for SCD in patients with non-ischemic cardiomyopathy experienced syncope presumed to be due to ventricular arrhythmia and not meeting indications for a primary prevention ICD, if the expected meaningful survival is > 1 year.

### Endomyocardial Biopsy

**As per ESC 2023 guidelines:**

(C)
- Consider performing an endomyocardial biopsy in patients with suspected cardiomyopathy to aid in diagnosis and management when the results of other clinical investigations suggest myocardial inflammation, infiltration, or storage that cannot be identified by other means.

## Medical Management

### General Principles

**As per ESC 2023 guidelines:**

(B)
- Ensure that all patients with cardiomyopathy and their relatives have access to multidisciplinary teams with expertise in the diagnosis and management of cardiomyopathies.
- Identify and manage risk factors and concomitant diseases as an integral part of the management of patients with cardiomyopathy.

### Antiarrhythmic Agents

**As per ESC 2022 guidelines:**

(C)
- Consider adding oral amiodarone or replacing β-blockers with sotalol in patients with dilated cardiomyopathy and an ICD experiencing recurrent, symptomatic ventricular arrhythmia despite optimal device programming and β-blocker treatment.

**As per ACC/AHA/HRS 2018 guidelines:**

(C)
- Consider initiating amiodarone for the prevention of SCD in patients with non-ischemic cardiomyopathy survived a cardiac arrest, having sustained VT or symptomatic ventricular arrhythmia, and are ineligible for an ICD (due to a limited life-expectancy and/or functional status or lack of access to an ICD).
- Consider initiating amiodarone or sotalol in patients with non-ischemic cardiomyopathy and an ICD experiencing spontaneous ventricular arrhythmia or recurrent appropriate shocks despite optimal device programming and treatment with a β-blocker.

### Management of AF (Atrial Fibrillation) - Antithrombotic Therapy

**As per ESC 2023 guidelines:**

(B)
- Initiate oral anticoagulation, unless contraindicated, to reduce the risk of stroke and thromboembolic events in all patients with HCM and AF or atrial flutter.
- Initiate oral anticoagulation to reduce the risk of stroke and thromboembolic events in patients with dilated cardiomyopathy or non-dilated LV cardiomyopathy and AF or atrial flutter with a CHA2DS2-VASc score ≥ 2 in males or ≥ 3 in females.

(C)  
- Consider initiating oral anticoagulation to reduce the risk of stroke and thromboembolic events in patients with dilated cardiomyopathy or non-dilated LV cardiomyopathy and AF or atrial flutter with a CHA2DS2-VASc score of 1 in males or 2 in females.

(B)
- Advise modifying unhealthy lifestyles and offer targeted therapy of intercurrent conditions to reduce AF burden and symptom severity in patients with cardiomyopathy.

### Management of AF (Atrial Fibrillation) - Catheter Ablation

**As per ESC 2023 guidelines:**

(B)
- Perform catheter ablation for rhythm control after one failed or intolerant class I or III antiarrhythmic drug to improve symptoms of recurrences in patients with paroxysmal or persistent AF and cardiomyopathy.
- Perform catheter ablation to reverse LV dysfunction in patients with AF when tachycardia-induced component is highly probable, independent of their symptom status.

(C)
- Consider ensuring maintenance of sinus rhythm rather than rate control at an early stage in patients with AF without major risk factors for recurrence, regardless of symptoms.
- Consider performing catheter ablation as first-line rhythm control therapy as an alternative to class I or III antiarrhythmic drugs, considering patient choice, benefit, and risk, to improve symptoms in selected patients with paroxysmal or persistent AF without major risk factors for recurrences.
- Consider performing catheter ablation to prevent AF recurrences and improve QoL, LVEF, and survival and reduce HF hospitalization in selected patients with AF and HF and/or reduced LVEF.

## Nonpharmacologic Interventions

### Physical Activity Restrictions

**As per ESC 2023 guidelines:**

(B)
- Advise practicing regular low-to-moderate-intensity exercise in all able patients with cardiomyopathy.
- Obtain an individualized risk assessment for exercise prescription in all patients with cardiomyopathy.
- Restrict high-intensity exercise, including competitive sport, in the presence of symptoms, an LVEF ≤ 40%, exercise-induced arrhythmias, or pathogenic variants in LMNA or TMEM43.

(C)
- Consider allowing moderate- and high-intensity exercise in gene-positive and phenotype-negative (with the exception of pathogenic variants in LMNA and TMEM43) patients seeking to do so.
- Consider allowing high-intensity exercise and participation in competitive sport in selected asymptomatic and optimally treated patients with an LVEF ≥ 50% in the absence of exercise-induced complex arrhythmias.
- Consider allowing moderate-intensity exercise in asymptomatic and optimally treated patients with an LVEF of 40-49% in the absence of exercise-induced complex arrhythmias.

### Psychological Support

**As per ESC 2023 guidelines:**

(B)
- Offer psychological support by an appropriately trained health professional in all patients with inherited cardiomyopathy receiving an implantable cardioverter defibrillator.
- Offer psychological support by an appropriately trained health professional in all persons who have experienced the premature SCD of a family member with cardiomyopathy.

(C)
- Consider offering psychological support by an appropriately trained health professional in all patients and families with inherited cardiomyopathy.

## Therapeutic Procedures

### ICD (Implantable Cardioverter Defibrillator) - General Principles

**As per ESC 2023 guidelines:**

(B)
- Perform ICD placement only in patients with an expected good quality survival > 1 year.
- Guide ICD implantation by shared decision-making that is evidence-based, takes into account the patient's individual preferences, beliefs, circumstances, and values, and ensures that the patient understands the benefits, harms, and possible consequences of different treatment options.
- Counsel patients before ICD implantation on the risk of inappropriate shocks, implant complications, and the social, occupational, and driving implications of the device.

(D)
- Do not perform ICD placement in patients with incessant ventricular arrhythmias until the ventricular arrhythmia is controlled.

### ICD - Primary Prevention of SCD

**As per ESC 2023 guidelines:**

(B)
- Consider performing ICD placement to reduce the risk of sudden death and all-cause mortality in patients with dilated cardiomyopathy, symptomatic HF, and LVEF ≤ 35% despite > 3 months of optimal medical therapy.

(C)
- Consider performing ICD placement in patients with dilated cardiomyopathy with a genotype associated with a high SCD risk and LVEF > 35% in the presence of additional risk factors.
- Consider performing ICD placement in selected patients with dilated cardiomyopathy with a genotype associated with a high SCD risk and LVEF > 35% without additional risk factors.
- Consider performing ICD placement in patients with dilated cardiomyopathy without a genotype associated with a high SCD risk and LVEF > 35% in the presence of additional risk factors.

**As per ESC 2022 guidelines:**

(B)
- Consider performing ICD placement in patients with dilated cardiomyopathy, symptomatic HF (NYHA class II-III), and LVEF ≤ 35% after ≥ 3 months of optimal medical treatment.

(C)
- Consider performing ICD placement in patients with dilated cardiomyopathy with a pathogenic mutation in the lamin A/C gene, if the estimated 5-year risk of life-threatening ventricular arrhythmia is ≥ 10% and in the presence of nonsustained VT or LVEF < 50% or atrioventricular conduction delay.
- Consider performing ICD placement in patients with dilated cardiomyopathy with an LVEF < 50% and ≥ 2 risk factors (syncope, late gadolinium enhancement on cardiac MRI, inducible sustained monomorphic VT at programmed electrical stimulation, pathogenic mutations in lamin A/C, PLN, FLNC, and RBM20 genes).

**As per ACC/AHA/HFSA 2022 guidelines:**

(A)
- Perform ICD placement for primary prevention of SCD to reduce total mortality in patients with non-ischemic dilated cardiomyopathy or ischemic heart disease at least 40 days post-myocardial infarction with LVEF ≤ 35% and NYHA class II-III symptoms on chronic guideline-directed medical therapy, if the expected meaningful survival is > 1 year.

**As per ACC/AHA/HRS 2018 guidelines:**

(A)
- Perform ICD placement in patients with non-ischemic cardiomyopathy, HF with NYHA class II-III symptoms, and LVEF of ≤ 35% despite guideline-directed medical therapy, if the expected meaningful survival is > 1 year.

(C)
- Consider performing ICD placement in patients with non-ischemic cardiomyopathy due to a Lamin A/C mutation having ≥ 2 risk factors (nonsustained VT, an LVEF < 45%, non-missense mutation, and male gender), if the expected meaningful survival is > 1 year.
- Consider performing ICD placement in patients with non-ischemic cardiomyopathy, HF with NYHA class I symptoms, and an LVEF ≤ 35% despite guideline-directed medical therapy, if the expected meaningful survival is > 1 year.

(D)
- Do not perform ICD placement in patients with medication-refractory NYHA class IV HF ineligible for cardiac transplantation, a LV assist device, or a CRT defibrillator incorporating both pacing and defibrillation capabilities.

### ICD - Secondary Prevention of SCD

**As per ESC 2023 guidelines:**

(B)
- Perform ICD placement to reduce the risk of sudden death and all-cause mortality in patients with dilated cardiomyopathy with a history of survived cardiac arrest or recovered from a ventricular arrhythmia causing hemodynamic instability.

**As per ESC 2022 guidelines:**

(B)
- Perform ICD placement in patients with dilated cardiomyopathy survived sudden cardiac arrest due to VT/VF or experienced hemodynamically not-tolerated sustained monomorphic VT.

(C)
- Consider performing ICD placement in patients with dilated cardiomyopathy and hemodynamically tolerated sustained monomorphic VT.

**As per ACC/AHA/HRS 2018 guidelines:**

(B)
- Perform ICD placement in patients with non-ischemic cardiomyopathy who either survived sudden cardiac arrest due to VT/VF or experienced hemodynamically unstable VT or stable sustained VT not due to reversible causes, if the expected meaningful survival is > 1 year.

(C)
- Consider performing ICD placement or obtaining electrophysiologic testing for risk stratification for SCD in patients with non-ischemic cardiomyopathy who experienced syncope presumed to be due to ventricular arrhythmia and are not meeting indications for a primary prevention ICD, if the expected meaningful survival is > 1 year.

### ICD - Technical Considerations

**As per ESC 2023 guidelines:**

(A)
- Evaluate patients for eligibility for CRT when an ICD is indicated.

(C)
- Consider placing subcutaneous defibrillators as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia, cardiac resynchronization, or anti-tachycardia pacing is not anticipated.
- Consider using wearable cardioverter-defibrillator in adult patients with a secondary prevention ICD indication temporarily ineligible for ICD placement.

### Catheter Ablation - Ventricular Arrhythmia

**As per ESC 2022 guidelines:**

(C)
- Consider performing catheter ablation in specialized centers in patients with dilated cardiomyopathy and recurrent, symptomatic sustained monomorphic VT or ICD shocks for sustained monomorphic VT, if antiarrhythmic drugs are ineffective, contraindicated, or not tolerated.

**As per ACC/AHA/HRS 2018 guidelines:**

(C)
- Consider performing catheter ablation for reducing recurrent VT and ICD shocks in patients with non-ischemic cardiomyopathy and recurrent sustained monomorphic VT failed or intolerant to antiarrhythmic medications.

### Catheter Ablation - AF

**As per ESC 2023 guidelines:**

(B)
- Perform catheter ablation for rhythm control after one failed or intolerant class I or III antiarrhythmic drug to improve symptoms of recurrences in patients with paroxysmal or persistent AF and cardiomyopathy.
- Perform catheter ablation to reverse LV dysfunction in patients with AF when tachycardia-induced component is highly probable, independent of their symptom status.

(C)
- Consider ensuring maintenance of sinus rhythm rather than rate control at an early stage in patients with AF without major risk factors for recurrence, regardless of symptoms.
- Consider performing catheter ablation as first-line rhythm control therapy as an alternative to class I or III antiarrhythmic drugs, considering patient choice, benefit, and risk, to improve symptoms in selected patients with paroxysmal or persistent AF without major risk factors for recurrences.
- Consider performing catheter ablation to prevent AF recurrences and improve QoL, LVEF, and survival and reduce HF hospitalization in selected patients with AF and HF and/or reduced LVEF.

## Perioperative Care

### Perioperative Assessment

**As per ESC 2023 guidelines:**

(B)
- Obtain perioperative ECG monitoring in all patients with cardiomyopathy undergoing noncardiac surgery.
- Re-evaluate LV function with echocardiography (assessing LVOTO in patients with HCM) and measurement of NT-proBNP/BNP levels (unless recently obtained) in patients with cardiomyopathy and suspected or known HF scheduled for intermediate or high-risk noncardiac surgery.
- Refer patients with cardiomyopathy with high-risk genotypes or associated factors for arrhythmic or HF complications or severe LVOTO to a cardiomyopathy unit for additional specialized investigations before undergoing elective noncardiac surgery.
- Obtain an ECG and TTE before noncardiac surgery, regardless of symptoms, in < 65 years old patients with a first-degree relative with cardiomyopathy.

## Surgical Interventions

### LV Assist Device

**As per ESC 2023 guidelines:**

(C)  
- Consider initiating mechanical circulatory support therapy in selected patients with cardiomyopathy with advanced HF (NYHA class III-IV) despite optimal pharmacological and device treatment, otherwise suitable for heart transplantation, to improve symptoms and reduce the risk of HF hospitalization from worsening HF and premature death while awaiting a transplant.
- Consider initiating mechanical circulatory support therapy in selected patients with cardiomyopathy with advanced HF (NYHA class III-IV) despite optimal pharmacological and device therapy, ineligible for cardiac transplantation or other surgical options, and without severe RV dysfunction, to reduce the risk of death and improve symptoms.

### Heart Transplantation

**As per ESC 2023 guidelines:**

(B)
- Offer orthotopic cardiac transplantation in eligible patients with cardiomyopathy with advanced HF (NYHA class III-IV) or intractable ventricular arrhythmia refractory to medical/invasive/device therapy in the absence of absolute contraindications.

## Specific Circumstances

### Athletes

**As per ESC 2022 guidelines:**

(B)
- Discourage participation in high-intensity exercise including competitive sports in patients with dilated cardiomyopathy and a lamin A/C mutation.

**As per ACC/AHA 2015 guidelines:**

(B)
- Discourage participation in most competitive sports in symptomatic athletes with dilated cardiomyopathy, with the possible exception of low-intensity (class 1A sports) in selected cases, at least until more information is available.

### Pediatric Patients - Evaluation

**As per AHA 2016 guidelines:**

(B)
- Exclude underlying causes such as primary arrhythmias, cardiotoxins, congestive heart disease, or other structural defects such as anomalous left coronary artery from the pulmonary artery before making the diagnosis of idiopathic dilated cardiomyopathy in pediatric patients with cardiomyopathy phenotype.
- Consider obtaining genetic testing to confirm the diagnosis, facilitate cascade screening within the family, and help with family planning in patients with familial dilated cardiomyopathy.
- Obtain mutation-specific genetic testing in family members and appropriate relatives after the identification of a dilated cardiomyopathy-causative mutation in the index case.

(A)
- Obtain comprehensive or targeted dilated cardiomyopathy genetic testing (LMNA and SCN5A) in patients with dilated cardiomyopathy and significant cardiac conduction disease (first-, second-, or third-degree heart block) or a family history of premature unexpected sudden death.

(C)
- Consider obtaining an ECG and echocardiographic screening for cardiomyopathy in first-degree relatives of pediatric patients with dilated cardiomyopathy phenotype.
- Consider measuring serum natriuretic peptide levels to follow the clinical course in pediatric patients with dilated cardiomyopathy phenotype.
- Consider obtaining nasal swabs and stool specimens to evaluate for viruses as well as blood PCR in patients with suspected myocarditis.
- Consider performing an endomyocardial biopsy to guide further therapy in young patients with clinical signs of myocarditis failing to recover.
- Consider performing a skeletal muscle biopsy and obtaining genetic testing in pediatric patients with dilated cardiomyopathy phenotype and musculoskeletal symptoms such as hypotonia.

### Pediatric Patients - Management

**As per AHA 2016 guidelines:**

(B)
- Initiate guideline-directed medical therapy for adult HF (including diuretic agents, β-blockers, ACEis, and other medications as appropriate) in pediatric patients with dilated cardiomyopathy.
- Offer mechanical assist devices and ECMO as a bridge to heart transplantation in pediatric patients with severe acute HF from dilated cardiomyopathy.
- Offer heart transplantation in pediatric patients with severe end-stage HF from dilated cardiomyopathy refractory to treatment.

(C)
- Consider performing ICD placement to prevent sudden death in high-risk patients with dilated cardiomyopathy.
- Consider administering IVIG in young patients with clinical or biopsy-proven myocarditis. Do not use corticosteroids in pediatric patients with clinical signs of myocarditis.

### Pregnant Patients

**As per ESC 2023 guidelines:**

(B)
- Obtain prenatal diagnostic testing early in pregnancy, if it is to be pursued by the family, to allow making decisions regarding continuation or coordination of pregnancy.
- Obtain pre-pregnancy risk assessment using the modified WHO classification of maternal risk and provide counseling in all female patients.
- Counsel on safe and effective contraception in all females of childbearing age and their partners.
- Counsel on the risk of disease inheritance in all male and female patients before conception.
- Offer vaginal delivery in most female patients with cardiomyopathies unless there are obstetric indications for C-section, severe HF (ejection fraction < 30% or NYHA class III-IV), or severe outflow tract obstructions, as well as in female patients presenting in labor on OACs.
- Obtain careful review of medications for safety before pregnancy and adjust according to tolerability in pregnancy.
- Initiate therapeutic anticoagulation with LMWH or VKAs in patients with AF according to the stage of pregnancy.

(C)
- Consider offering discussion about reproductive genetic testing options with an appropriately trained healthcare professional in all families with a genetic diagnosis.
- Consider continuing β-blockers during pregnancy with close follow-up of fetal growth and of the condition of the neonate if the benefits outweigh the risks.
- Consider obtaining genetic testing and providing genetic counseling in patients with peripartum cardiomyopathy.

### Patients with Non-Dilated LV Cardiomyopathy - ICD Implantation, Primary Prevention of SCD

**As per ESC 2023 guidelines:**

(B)
- Take into consideration the patient's genotype in the estimation of SCD risk in non-dilated LV cardiomyopathy.
- Consider performing ICD placement to reduce the risk of sudden death and all-cause mortality in patients with non-dilated LV cardiomyopathy, HF symptoms, and LVEF ≤ 35% despite > 3 months of optimal medical therapy.

(C)
- Consider performing ICD placement in patients with non-dilated LV cardiomyopathy with a genotype associated with a high SCD risk and LVEF > 35% in the presence of additional risk factors.
- Consider performing ICD placement in selected patients with non-dilated LV cardiomyopathy with a genotype associated with a high SCD risk and LVEF > 35% without additional risk factors.
- Consider performing ICD placement in patients with non-dilated LV cardiomyopathy without a genotype associated with a high SCD risk and LVEF > 35% in the presence of additional risk factors.

### Patients with Non-Dilated LV Cardiomyopathy - ICD Implantation, Secondary Prevention of SCD

**As per ESC 2023 guidelines:**

(B)
- Perform ICD placement to reduce the risk of sudden death and all-cause mortality in patients with non-dilated LV cardiomyopathy with a history of survived cardiac arrest or recovered from a ventricular arrhythmia causing hemodynamic instability.

### Patients with Cardiac Amyloidosis - Evaluation

**As per AHA 2016 guidelines:**

(C)
- Consider performing an endomyocardial biopsy to identify amyloid protein in cardiac tissue in patients with suspected cardiac amyloidosis, especially if there is no noncardiac tissue evidence of amyloidosis.
- Consider obtaining imaging and further laboratory tests or biopsies to identify affected organs in patients with an established diagnosis of amyloidosis.
- Consider measuring natriuretic peptide (BNP or NT-proBNP) levels to detect early/preclinical cardiac involvement in patients with the diagnosis of amyloidosis and to predict future cardiac involvement and prognosis.
- Consider using noncardiac tissue-proven amyloidosis along with echocardiographic or cardiac MRI findings suggestive of infiltrative cardiomyopathy and symptoms and signs of HF to diagnose cardiac amyloidosis without performing an endomyocardial biopsy.
- Consider using the presence of serum or urine monoclonal gammopathy suggesting the presence of AL amyloidosis along with echocardiographic or cardiac MRI findings suggestive of infiltrative cardiomyopathy and symptoms and signs of HF to support the diagnosis (not definitive diagnosis) of cardiac amyloidosis without performing an endomyocardial biopsy.
- Consider using certain ECG features, such as the presence of low QRS voltage in the presence of ventricular wall thickening, to suggest the presence of cardiac amyloidosis but not to confirm the diagnosis of cardiac amyloidosis.
- Consider obtaining nuclear imaging with technetium Tc99m dicarboxypropane diphosphonate to distinguish between AL and TTR amyloidosis.

(B)
- Assess for amyloid protein in tissues such as abdominal fat pad, gingiva, or rectum or affected organs such as heart, liver, and kidney to diagnose amyloidosis in patients with suspected cardiac and systemic amyloidosis.
- Obtain DNA mutational analysis to differentiate between senile and hereditary amyloidosis if TTR amyloid is detected from a biopsy specimen.
- Obtain echocardiography in patients with suspected cardiac amyloidosis or patients with systemic amyloidosis and HF.

### Patients with Cardiac Amyloidosis - Management

**As per AHA 2016 guidelines:**

(A)
- Initiate warfarin therapy (with a goal INR of 2-3) or direct thrombin inhibitors in patients with cardiac amyloidosis and paroxysmal or chronic AF or a history of embolic stroke/TIA.

(C)
- Consider initiating warfarin therapy (with a goal INR of 2-3) in patients with imaging-proven intracardiac thrombus.
- Consider administering diuretic agents in patients with HF symptoms and congestion while avoiding over-diuresis and volume contraction leading to hypotension.
- Consider administering β-blockers to increase diastolic filling time and control HR in the setting of AF, while being cautious because cardiac output is HR dependent in the setting of severe restrictive physiology or low-output HF.
- Consider offering high-dose chemotherapy followed by autologous hematopoietic cell transplantation in selected patients with AL amyloidosis with cardiac involvement and LVEF ≥ 40% and compensated HF status.
- Consider offering certain combinations of chemotherapeutic agents to improve survival in patients with AL amyloidosis ineligible for autologous hematopoietic cell transplantation.
- Consider offering cardiac and liver transplantation in selected patients with TTR-related amyloidosis.
- Consider offering cardiac transplantation followed by bone marrow transplantation in very selected patients with AL amyloidosis.

(D)
- Avoid using digoxin in patients with amyloidosis.
- Do not use CCBs (nifedipine or verapamil) because they bind to amyloid fibrils and can result in exaggerated hypotensive and negative inotropic responses.

(B)
- Offer device-based therapy (taking into account life expectancy) in patients with cardiac amyloidosis having cardiac rhythm abnormalities.

**Updated Evidence - ATTRibute-CM Study:**
In patients with transthyretin amyloid cardiomyopathy, acoramidis was superior to placebo with respect to favorable pairwise comparisons in a hierarchical outcome of death from any cause, cardiovascular-related hospitalization, change from baseline in the NT-proBNP level, and change from baseline in the 6-minute walk distance at month 30.
**Reference:** Julian D Gillmore et al. N Engl J Med. 2024 Jan 11. [PubMed](https://pubmed.ncbi.nlm.nih.gov/search/?term=Julian+D+Gillmore+ATTRibute-CM+2024)

### Patients with Alcoholic Cardiomyopathy

**As per AHA 2016 guidelines:**

(B)
- Advise total abstinence in patients with alcoholic cardiomyopathy.

### Patients with Cocaine-Related Cardiomyopathy

**As per AHA 2016 guidelines:**

(C)
- Consider initiating standard therapy for LV dysfunction, including β-blockers, in patients with cocaine-related cardiomyopathy with demonstrated abstinence for > 6 months.
- Consider initiating nonselective β-blocker treatment with α-1, β-1, or β-2 receptor antagonism in patients at risk for relapse of cocaine abuse because of the potential protection against the unopposed α-agonism effects of cocaine with β-1 receptor antagonist treatment alone.

(B)
- Advise total abstinence from cardiotoxic agents and drugs in patients with cardiomyopathy related to substance abuse or overdose.

### Patients with Chemotherapy-Related Cardiomyopathy

**As per AHA 2016 guidelines:**

(B)
- Obtain cardiac functional assessment with LVEF measurement at baseline, after completing treatment, and while on treatment at regular intervals, or sooner if HF symptoms develop in patients treated with cardiotoxic chemotherapeutic agents.
- Obtain a careful evaluation of the benefit of continued therapy against the risk of producing irreversible cardiac damage when test results indicate deterioration in cardiac function associated with cardiotoxic chemotherapy.
- Initiate guideline-directed medical therapy for systolic HF in patients with malignancy.
- Offer strategies such as administration of divided continuous infusions, liposome encapsulation, use of less cardiotoxic derivatives, or use of cardioprotective agents such as dexrazoxane in conjunction with treatment to reduce cardiotoxicity of doxorubicin chemotherapy in patients at high risk for cardiac toxicity.

(C)
- Consider measuring cardiac troponin to identify patients at risk of cardiotoxicity with cancer therapy.

**I Level Evidence (Insufficient Evidence):**
- Insufficient evidence to recommend serial/repeated measurements of cardiac biomarkers for monitoring cardiotoxicity with cancer therapy.
- Insufficient evidence to support the use of β-blockers, ACEis, or ARBs for primary prevention of cardiac toxicity of chemotherapy.

### Patients with Peripartum Cardiomyopathy - Evaluation

**As per AHA 2016 guidelines:**

(B)
- Ensure timely diagnosis of peripartum cardiomyopathy to prevent delay of treatment and potential related complications.
- Include the following criteria for the diagnosis of peripartum cardiomyopathy:
  - history confirming the onset of HF began in the last months of pregnancy or the months after delivery
  - presence of LV dysfunction
  - exclusion of other reasons for cardiomyopathy
- Obtain cardiac imaging to assess the presence and extent of LV dysfunction, the degree of dilation, and the presence of an intracardiac thrombus at the presentation of peripartum cardiomyopathy.

(D)
- Do not use gadolinium during cardiac MRI because of the potential harm to the fetus during pregnancy.

**I Level Evidence (Insufficient Evidence):**
- Insufficient evidence to support the use of cardiac imaging including echocardiography and cardiac MRI in predicting recovery from peripartum cardiomyopathy.
- Insufficient evidence to support the use of cardiac biomarkers such as cardiac troponin or natriuretic peptides for diagnosis, prognosis, or prediction of the recovery in patients with peripartum cardiomyopathy.

### Patients with Peripartum Cardiomyopathy - Management

**As per AHA 2016 guidelines:**

(B)
- Manage patients with peripartum cardiomyopathy by a multidisciplinary team including cardiologists, high-risk obstetricians, and perinatologists, as well as possibly cardiac anesthesiologists, cardiac intensivists, and pediatricians.
- Refer pregnant patients with peripartum cardiomyopathy to a center with experience with this condition for multidisciplinary care, with close monitoring before, during, and after delivery.
- Continue standard HF medications indefinitely in patients with peripartum cardiomyopathy if the LV function fails to normalize.
- Initiate prompt delivery in pregnant patients with peripartum cardiomyopathy with an unstable condition or having maternal extremis.
- Counsel patients with peripartum cardiomyopathy failed to normalize ventricular function after pregnancy against a subsequent pregnancy because of the significant risk of morbidity and mortality.
- Obtain close clinical follow-up with an annual assessment of LVEF for a minimum of several years after recovery, particularly if subsequent pregnancy is still being considered.
- Discourage subsequent pregnancy in patients with a history of peripartum cardiomyopathy and persistent LV dysfunction because of the significant mortality risk.

(C)
- Consider initiating guideline-directed medical therapy known to benefit patients with LV dysfunction (ACEis, ARBs, β-blockers, and aldosterone antagonists) and HF, taking into account both pregnancy and breastfeeding status because certain classes of medications may not be safe during pregnancy or lactation, for example, ACEis, ARBs, and warfarin are potentially harmful during pregnancy because of significant fetal risks.
- Consider initiating anticoagulation to prevent thrombus formation in patients with peripartum cardiomyopathy and severe LV dysfunction given the risk of a hypercoagulable state during pregnancy.
- Consider offering cardiac device therapy with an ICD, CRT, or both, in patients with peripartum cardiomyopathy if the ventricular function fails to normalize after pregnancy.
- Consider allowing for ≥ 6 months of standard medical therapy in patients with peripartum cardiomyopathy to allow for possible myocardial recovery when considering the timing of placement of a cardiac device, such as an ICD, with or without CRT.
- Consider offering wearable defibrillator life vests in high-risk patients with LVEF < 35% while waiting for a response to medical therapy in the absence of a clear indication for an ICD.
- Consider offering temporary or bridge mechanical circulatory support or heart transplantation in patients with peripartum cardiomyopathy not responding to medical therapy and requiring continuous inotropic therapy.

**I Level Evidence (Insufficient Evidence):**
- Insufficient evidence regarding the efficacy and safety of experimental therapies such as bromocriptine or pentoxifylline for the treatment of peripartum cardiomyopathy.

### Patients with Cardiac Sarcoidosis

**As per AHA 2016 guidelines:**

(B)
- Obtain echocardiography to assess LVEF in patients with signs and symptoms of HF.
- Refer patients with advanced HF for cardiac transplantation or mechanical circulatory support in the absence of significant extracardiac burden of sarcoid disease.

(C)
- Consider obtaining cardiac MRI or PET imaging with FDG imaging to diagnose cardiac sarcoidosis or follow the response to therapy.
- Consider performing an endomyocardial biopsy to confirm cardiac sarcoidosis when pathology yields evidence of noncaseating granulomas, recognizing that the absence of evidence does not rule out the possibility of cardiac sarcoidosis.

(B)
- Initiate standard guideline-directed medical therapy for HFrEF in patients with cardiac sarcoidosis.
- Offer corticosteroids in patients with cardiac sarcoidosis.

(C)
- Consider offering immunosuppressive therapies (such as methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide, pentoxifylline, or thalidomide) in patients unable to tolerate corticosteroids and in patients continuing to worsen clinically despite treatment with corticosteroids.
- Consider offering immune-modulating therapy in patients with sarcoidosis in collaboration with a pulmonologist or rheumatologist.
- Consider performing ICD placement in patients with cardiac sarcoidosis.

### Patients with Acute Myocarditis

**As per AHA 2016 guidelines:**

(B)
- Obtain a 12-lead ECG, TTE, and cardiac troponins in all patients with clinically suspected myocarditis.
- Manage patients with HF caused by clinically suspected or confirmed myocarditis according to the current HF guidelines.
- Discourage patients with HF caused by clinically suspected or confirmed myocarditis from competitive sports for a minimum of 3-6 months.
- Initiate immunosuppressive therapy including calcineurin inhibitors and corticosteroids for the treatment of acute dilated cardiomyopathy caused by giant cell myocarditis.

(C)
- Consider obtaining cardiac MRI for the diagnosis of myocarditis in clinically stable patients with clinically suspected myocarditis.
- Consider performing an endomyocardial biopsy in patients with clinically suspected myocarditis. Perform an endomyocardial biopsy in patients with clinically suspected unexplained acute myocarditis requiring inotropic support or mechanical circulatory support and in patients with Mobitz type 2 second-degree or higher heart block, sustained or symptomatic VT, or failure to respond to guideline-based medical management within 1-2 weeks.
- Consider providing advanced cardiac support according to the current guidelines, including mechanical circulatory support and listing for heart transplantation, in patients with HF caused by clinically suspected or confirmed myocarditis.

(D)
- Do not perform ICD placement in patients with recent-onset dilated cardiomyopathy and LVEF < 30% caused by clinically suspected or confirmed myocarditis in the absence of ventricular arrhythmias or syncope.

### Patients with Eosinophilic Myocarditis

**As per AHA 2016 guidelines:**

(C)
- Consider performing an endomyocardial biopsy in patients with suspected eosinophilic myocarditis.

### Patients with HIV-Associated Cardiomyopathy

**As per AHA 2016 guidelines:**

(B)
- Screen for HIV as a possible cause of dilated cardiomyopathy in patients with dilated cardiomyopathy and risk factors for HIV.
- Initiate antiretroviral therapy for prevention and treatment of dilated cardiomyopathy related to HIV infection.
- Initiate standard guideline-directed medical and device therapies for systolic HF in patients with HIV cardiomyopathy.

### Patients with Chagas Cardiomyopathy

**As per ESC 2022 guidelines:**

(C)
- Consider initiating amiodarone to reduce the arrhythmia burden in patients with Chagas cardiomyopathy presenting with symptomatic premature ventricular complexes or VT.
- Consider performing catheter ablation in specialized centers in patients with Chagas cardiomyopathy and recurrent, symptomatic sustained monomorphic VT or ICD shocks for sustained monomorphic VT, if antiarrhythmic drugs are ineffective, contraindicated, or not tolerated.
- Consider performing ICD placement in patients with Chagas cardiomyopathy and symptomatic VT, if antiarrhythmic drugs (amiodarone and β-blockers) are ineffective or not tolerated.

**As per AHA 2016 guidelines:**

(B)
- Screen for Chagas disease in patients with dilated cardiomyopathy and epidemiological risk factors for Chagas disease, such as origin from Central or South America or exposure to infected vectors.

### Patients with Autoimmune Cardiomyopathy

**As per AHA 2016 guidelines:**

(C)
- Consider obtaining cardiac biomarkers such as natriuretic peptides (BNP, NT-proBNP) and cardiac troponin to identify patients with the autoimmune disease with or at risk for HF.
- Consider obtaining cardiac MRI or FDG PET imaging to identify patients at risk for HF and the degree of fibrosis.
- Consider performing an endomyocardial biopsy to confirm hydroxychloroquine-mediated HF.
- Consider offering IV corticosteroids, systemic immunosuppressants, or immunomodulatory agents in patients with biopsy-proven myocarditis believed to be caused by SLE, rheumatoid arthritis, or polyarteritis nodosa.
- Consider referring patients with advanced HF for cardiac transplantation or mechanical circulatory support in the absence of significant extracardiac burden of autoimmune disease.

(B)
- Evaluate patients with progressive signs and symptoms of HF by a cardiologist.
- Obtain echocardiography to assess cardiac function and structure in patients with signs and symptoms of HF.
- Obtain coronary angiography to exclude atherosclerosis in patients with dilated cardiomyopathy and autoimmune disease.
- Initiate guideline-directed medical and device therapies for systolic HF according to current guidelines.
- Optimize hypertension control in patients with autoimmune-mediated HF.
- Offer immune-modulating therapy without cardiac toxicity in collaboration with a rheumatologist for the treatment of the underlying autoimmune condition in patients with HF.

(D)
- Do not perform a routine endomyocardial biopsy in patients with cardiomyopathy caused by suspected autoimmune, rheumatologic, or collagen vascular disease.

### Patients with Obesity Cardiomyopathy

**As per AHA 2016 guidelines:**

(B)
- Obtain standard guideline-directed workup for assessment of the pathogenesis and prognosis in patients with HF and obesity.
- Offer standard guideline-directed medical therapy for HF in patients with HF and obesity.
- Advise participating in exercise training (or regular physical activity) as safe and effective in patients with HF able to participate to improve functional status, including patients with obesity.

(C)
- Consider offering purposeful weight loss via healthy dietary intervention, physical activity, or weight-loss drugs (such as orlistat) for the purposes of improving health-related QoL or managing comorbidities (such as diabetes mellitus, hypertension, or sleep apnea) in patients with HF and obesity.

**I Level Evidence (Insufficient Evidence):**
- Insufficient evidence to recommend purposeful weight reduction, including bariatric surgery, dietary intervention, or weight-loss drugs (such as orlistat) to reduce morbidity or mortality in patients with HF.

### Patients with GH Cardiomyopathy

**As per AHA 2016 guidelines:**

(B)
- Test for acromegaly or GHD in patients with dilated cardiomyopathy with other signs and symptoms of those clinical disorders.
- Treat the primary disorder of excess or deficiency of GH in all patients with coexisting dilated cardiomyopathy.

### Patients with Tachycardia-Induced Cardiomyopathy

**As per AHA 2016 guidelines:**

(B)
- Ensure maintenance of sinus rhythm or control of ventricular in treating patients with tachycardia-induced cardiomyopathy.

### Patients with LBBB-Induced Cardiomyopathy

**As per AHA 2016 guidelines:**

(C)
- Consider offering CRT in patients with suspected cardiomyopathy caused by LBBB.

### Patients with PVC-Induced Cardiomyopathy - Evaluation

**As per ESC 2022 guidelines:**

(B)
- Suspect premature ventricular complex-induced cardiomyopathy in patients with unexplained reduced ejection fraction and premature ventricular complex burden of at least 10%.

(C)
- Consider obtaining cardiac MRI in patients with suspected premature ventricular complex-induced cardiomyopathy.

### Patients with PVC-Induced Cardiomyopathy - Management

**As per ESC 2022 guidelines:**

(B)
- Perform catheter ablation in patients with cardiomyopathy suspected to be caused by frequent and predominantly monomorphic premature ventricular complexes.

(C)
- Consider initiating antiarrhythmic drugs in patients with cardiomyopathy suspected to be caused by frequent and predominantly monomorphic premature ventricular complexes, if catheter ablation is not desired, suspected to be high-risk or unsuccessful.
- Consider initiating antiarrhythmic drugs (amiodarone) or performing catheter ablation in patients with structural heart disease when predominantly monomorphic frequent premature ventricular complexes are suspected to be contributing to the cardiomyopathy.
- Consider performing catheter ablation or initiating antiarrhythmic drugs in nonresponders to CRT with frequent, predominantly monomorphic premature ventricular complexes limiting optimal biventricular pacing despite pharmacological therapy.

**As per ACC/AHA/HRS 2018 guidelines:**

(B)
- Consider performing catheter ablation in patients with recurrent episodes of idiopathic VF initiated by premature ventricular complexes with a consistent QRS morphology.
- Consider performing catheter ablation in patients requiring arrhythmia suppression for symptoms or declining ventricular function suspected to be due to frequent premature ventricular complexes (generally > 15% of beats and predominately of 1 morphology) and if antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference.

(C)
- Consider initiating pharmacologic treatment (such as β-blockers and amiodarone) to reduce recurrent arrhythmias and improve symptoms and LV function in patients with premature ventricular complex-induced cardiomyopathy.

**As per AHA 2016 guidelines:**

(C)
- Consider offering radiofrequency ablation in patients with premature ventricular contraction-induced cardiomyopathy.

### Patients with Iron-Overload Cardiomyopathy

**As per AHA 2016 guidelines:**

(B)
- Screen for iron overload including serum ferritin and transferrin saturation when evaluating a new case of cardiomyopathy.
- Obtain cardiac MRI in the setting of transferrin saturation > 45% or ferritin > 250 mcg/L (males) or > 200 mcg/L (females).

### Patients with Storage Disease Cardiomyopathy

**As per AHA 2016 guidelines:**

(B)
- Initiate enzyme replacement therapy in patients with Pompe or Fabry lysosomal storage disorder.

### Patients with Thyroid Disorders

**As per AHA 2016 guidelines:**

(B)
- Obtain thyroid function tests as part of the initial workup in all patients with dilated cardiomyopathy.
- Treat hypothyroidism and hyperthyroidism. Consider initiating β-blockers in patients with cardiac-related symptoms and signs of hyperthyroidism.

### Patients with Ischemic Stroke

**As per AHA/ASA 2021 guidelines:**

(B)
- Initiate warfarin for at least 3 months to reduce the risk of recurrent stroke or TIA in patients with ischemic stroke or TIA and LA or LAA thrombus in the setting of ischemic or non-ischemic cardiomyopathy and LV dysfunction.
- Individualize the decision between anticoagulation and antiplatelet therapy in patients with ischemic stroke or TIA in sinus rhythm with ischemic or non-ischemic cardiomyopathy and reduced ejection fraction without evidence of LA or LV thrombus.

## Patient Education

### Genetic Counseling

**As per ESC 2023 guidelines:**

(B)
- Provide genetic counseling by an appropriately trained healthcare professional, including genetic education, to inform decision-making and psychosocial support in families with an inherited or suspected inherited cardiomyopathy, regardless of whether genetic testing is being considered.
- Provide pre- and post-test genetic counseling in all individuals undergoing genetic testing for cardiomyopathy.

## Follow-up and Surveillance

### Follow-up

**As per ESC 2023 guidelines:**

(B)
- Obtain routine follow-up using a multiparametric approach with ECG and echocardiography every 1-2 years in all clinically stable patients with cardiomyopathy.
- Obtain clinical evaluation with ECG and multimodality imaging in patients with cardiomyopathy in case of a substantial or unexpected change in symptoms.
- Obtain a comprehensive evaluation of cardiac dimensions and LV and RV systolic (global and regional) and LV diastolic function during follow-up to monitor disease progression and aid risk stratification and management.
- Ensure timely and adequate preparation for the transition of care from pediatric to adult services, including joint consultations, for all adolescent patients with cardiomyopathy.

(C)
- Consider obtaining contrast-enhanced cardiac MRI during follow-up to monitor disease progression and aid risk stratification and management in patients with cardiomyopathy.

### Transition to Adult Care

**As per ESC 2023 guidelines:**

(B)
- Ensure timely and adequate preparation for the transition of care from pediatric to adult services, including joint consultations, for all adolescent patients with cardiomyopathy.

## References

1. Elena Arbelo, Alexandros Protonotarios, Juan R Gimeno et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1;44(37):3503-3626. [Open Access](https://academic.oup.com/eurheartj/article/44/37/3503/7207593) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/37622654)

2. Biykem Bozkurt, Monica Colvin, Jennifer Cook et al. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. Circulation. 2016 Dec 6;134(23):e579-e646. [Open Access](https://www.ahajournals.com/doi/10.1161/CIR.0000000000000455) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/27832612)

3. Sana M Al-Khatib, William G Stevenson, Michael J Ackerman et al. 2017 AHA / ACC / HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018 Sep 25;138(13):e272-e391. [Open Access](https://www.ahajournals.com/doi/10.1161/CIR.0000000000000549) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/29084731)

4. Katja Zeppenfeld, Jacob Tfelt-Hansen, Marta de Riva et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022 Oct 21;43(40):3997-4126. [Open Access](https://academic.oup.com/eurheartj/article/43/40/3997/6659349) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/36017572)

5. Paul A Heidenreich, Biykem Bozkurt, David Aguilar et al. 2022 AHA / ACC / HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-e1032. [Open Access](https://www.ahajournals.com/doi/10.1161/CIR.0000000000001063) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/35363499)

6. Dawn O Kleindorfer, Amytis Towfighi, Seemant Chaturvedi et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association / American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. [Open Access](https://www.ahajournals.com/doi/10.1161/STR.0000000000000375) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/34024117)

7. Michael J Ackerman, Silvia G Priori, Stephan Willems et al. HRS / EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm. 2011 Aug;8(8):1308-39. [Open Access](https://www.heartrhythmjournal.com/article/S1547-5271(11)00465-9/fulltext) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21787999)

8. Theresa A McDonagh, Marco Metra, Marianna Adamo et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. [Open Access](https://academic.oup.com/eurheartj/article/42/36/3599/6358045) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/34447992)

9. Barry J Maron, James E Udelson, Robert O Bonow et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation. 2015 Dec 1;132(22):e273-80. [Open Access](https://www.ahajournals.com/doi/10.1161/CIR.0000000000000239) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/26621644)

10. Anand Padmanabhan, Laura Connelly-Smith, Nicole Aqui et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019 Jun;34(3):171-354. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30903640)

11. Expert Panel on Cardiac Imaging, Prabhakar Rajiah, Jacobo Kirsch et al. ACR Appropriateness Criteria® Nonischemic Myocardial Disease with Clinical Manifestations (Ischemic Cardiomyopathy Already Excluded). J Am Coll Radiol. 2021 May;18(5S):S83-S105. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33958130)

12. Yigal M Pinto, Perry M Elliott, Eloisa Arbustini et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016 Jun 14;37(23):1850-8. [PubMed](https://pubmed.ncbi.nlm.nih.gov/26792875)

13. Tao Li, Guoliang Yuan, Chengbin Ma et al. Clinical efficacy of carvedilol treatment for dilated cardiomyopathy: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019 May;98(18):e15403. [Open Access](https://journals.lww.com/md-journal/fulltext/2019/05030/clinical_efficacy_of_carvedilol_treatment_for.36.aspx) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/31045755)

14. Robert G Weintraub, Christopher Semsarian, Peter Macdonald. Dilated cardiomyopathy. Lancet. 2017 Jul 22;390(10092):400-414. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28190580)

15. Rachel Lampert, Eugene H Chung, Michael J Ackerman et al. 2024 HRS expert consensus statement on arrhythmias in the athlete: Evaluation, treatment, and return to play. Heart Rhythm. 2024 Oct;21(10):e151-e252. [Open Access](https://www.heartrhythmjournal.com/article/S1547-5271(24)02738-3/fulltext) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/38964577)

